TY - JOUR
T1 - Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α-interferon and oral tegafur/uracil
AU - Miyamoto, Atsushi
AU - Umeshita, Koji
AU - Sakon, Masato
AU - Nagano, Hiroaki
AU - Eguchi, Hidetoshi
AU - Kishimoto, Shin Ichi
AU - Dono, Keizo
AU - Nakamori, Shoji
AU - Gotoh, Mitsukazu
AU - Monden, Morito
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of α-interferon (IFN-α) and tegafur/uracil (UFT). A 44-year-old Japanese man who underwent a partial hepatectomy for HCC developed tumor recurrence in the liver 10 months after surgery. Transcatheter arterial chemoembolization (TAE) was performed twice within 7 months, but was ineffective. Later, multiple metastatic lesions appeared in the liver, lung and spine. Following the third TAE, a combination therapy of IFN-α (10 × 106 units, i.m., t.i.w.) and UFT (300 mg, p.o.d.) was started. The treatment resulted in a fall in serum PIVKA-II (protein induced by vitamin K antagonism) levels from 906 mAU to normal levels and a complete resolution of all lung nodules within 6 months. At the latest follow up 24 months after the initiation of combination treatment, the patient was working full-time and showed no evidence of tumor relapse. A combination therapy of IFN-α and UFT may be promising for the treatment of advanced HCC.
AB - We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of α-interferon (IFN-α) and tegafur/uracil (UFT). A 44-year-old Japanese man who underwent a partial hepatectomy for HCC developed tumor recurrence in the liver 10 months after surgery. Transcatheter arterial chemoembolization (TAE) was performed twice within 7 months, but was ineffective. Later, multiple metastatic lesions appeared in the liver, lung and spine. Following the third TAE, a combination therapy of IFN-α (10 × 106 units, i.m., t.i.w.) and UFT (300 mg, p.o.d.) was started. The treatment resulted in a fall in serum PIVKA-II (protein induced by vitamin K antagonism) levels from 906 mAU to normal levels and a complete resolution of all lung nodules within 6 months. At the latest follow up 24 months after the initiation of combination treatment, the patient was working full-time and showed no evidence of tumor relapse. A combination therapy of IFN-α and UFT may be promising for the treatment of advanced HCC.
UR - http://www.scopus.com/inward/record.url?scp=0034526714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034526714&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1746.2000.02289.x
DO - 10.1046/j.1440-1746.2000.02289.x
M3 - Article
C2 - 11197059
AN - SCOPUS:0034526714
SN - 0815-9319
VL - 15
SP - 1447
EP - 1451
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
IS - 12
ER -